Lakewood-Amedex Biotherapeutics Inc. SEC filings LABT

Lakewood-Amedex Biotherapeutics Inc. has 44 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

Lakewood-Amedex Biotherapeutics Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 6, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Jun 23, 2026 —
4 Insider transaction May 6, 2026 Apr 24, 2026
3 Initial insider ownership May 6, 2026 Apr 24, 2026
3 Initial insider ownership May 1, 2026 Apr 17, 2026
3 Initial insider ownership May 1, 2026 Apr 17, 2026
3 Initial insider ownership May 1, 2026 Apr 17, 2026
3 Initial insider ownership May 1, 2026 Apr 17, 2026

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LABT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
University Park, FL
SEC filer status
, Emerging growth company
SEC CIK
2079272

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.